Stay updated on Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.3 to v3.5.0. No visible changes to the study details page were observed.
    Difference
    0.1%
    Check dated 2026-03-22T11:32:05.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    Revision label updated to v3.4.3 (replacing the previous v3.4.2).
    Difference
    0.1%
    Check dated 2026-03-08T01:52:00.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    No additions or deletions are detected in the provided page context. The page content appears unchanged between screenshots.
    Difference
    0.1%
    Check dated 2026-02-28T19:33:39.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.1 to v3.4.2 in the page footer. No study content or results appear affected.
    Difference
    0.1%
    Check dated 2026-02-14T12:46:25.000Z thumbnail image
  8. Check
    62 days ago
    Change Detected
    Summary
    Site footer/template revision updated from v3.4.0 to v3.4.1; no other content or functionality changes are evident. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-07T06:47:21.000Z thumbnail image
  9. Check
    76 days ago
    Change Detected
    Summary
    Additions include Show glossary, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0; Deletions include Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4. These changes pertain to UI labels and documentation metadata rather than core study content; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-24T03:19:59.000Z thumbnail image

Stay in the know with updates to Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.